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Abstract
 
Whereas CD40–CD40 ligand interactions are important for various dendritic cell (DC) func-
tions in vitro, their in vivo relevance is unknown. We analyzed the DC status of CD40 ligand
 
2
 
/
 
2
 
 mice using a contact hypersensitivity (CHS) model system that enables multiple functions
of DCs to be assessed in vivo. Immunohistochemistry of skin sections revealed no differences in
terms of numbers and morphology of dendritic epidermal Langerhans cells (LCs) in unsensi-
tized CD40 ligand 
 
2
 
/
 
2
 
 mice as compared with wild-type C57BL/6 mice. However, after
contact sensitization of CD40 ligand 
 
2
 
/
 
2
 
 mice, LCs failed to migrate out of the skin and sub-
stantially fewer DCs accumulated in draining lymph nodes (DLNs). Furthermore, very few an-
tigen-bearing DCs could be detected in the paracortical region of lymph nodes draining sensi-
tized skin. This defect in DC migration after hapten sensitization was associated with defective
CHS responses and decreased cutaneous tumor necrosis factor (TNF)-
 
a
 
 production and was
corrected by injecting recombinant TNF-
 
a
 
 or an agonistic anti-CD40 monoclonal antibody.
Thus, CD40–CD40 ligand interactions in vivo regulate the migration of antigen-bearing DCs
from the skin to DLNs via TNF-
 
a
 
 production and play a vital role in the initiation of acquired
T cell–mediated immunity.
Key words: Langerhans cells • epidermis • TNF-
 
a
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Introduction
 
A critical event in the initiation of acquired immune re-
sponses is the ferrying of Ag from peripheral nonlymphoid
tissues to secondary lymphoid organs, where low fre-
quency, Ag-specific lymphocytes congregate in discrete
histological niches (1). This transport of Ag is efficiently
 
performed by dendritic cells (DCs),
 
1
 
 a network of sentinel
cells strategically located at the boundaries between the im-
mune system and the environment that functions to initiate
immune responses (1, 2). Although it is known that several
molecules on DCs influence their ability to activate naive
T cells (1, 2), pathways through which T cells might affect
DCs remain unknown. One of the most dramatic influ-
ences on DCs is provided by CD40 stimulation in vitro (3,
4), raising the possibility that in vivo, some DC functions
might be dependent on CD40–CD40 ligand interactions.
Although functional CD40 has been found on DCs, B
cells, monocytes, endothelium, and keratinocytes, expres-
sion of CD40 ligand appears to be restricted to activated T
cells, activated platelets, basophils, and mast cells.
The clinical relevance of CD40–CD40 ligand interac-
tions is highlighted in the life-threatening manifestations of
Hyper IgM syndrome (HIM), where accumulation of IgM
and the inability of B cells to isotype switch has been attrib-
uted to mutated CD40 ligand on helper T cells (5, 6).
However, these defective humoral responses do not fully
explain the increased opportunistic infections seen in these
patients, an indication of impaired T cell responses (5, 6).
Indeed, cellular immunity has been shown to be impaired
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when CD40–CD40 ligand interactions are disrupted (5),
though the precise mechanisms remain unclear. Blocking
CD40–CD40 ligand interplay dramatically prolongs cardiac
and skin allograft survival and inhibits T cell–proliferative
responses both in vitro and in vivo (7). Likewise, develop-
ment of experimental allergic encephalomyelitis (EAE) in
myelin basic protein (MBP)–TCR-transgenic mice is also
blocked when these animals lack CD40 ligand (5). Interest-
ingly, Ag-specific responses are intact in MBP–TCR
CD40 ligand 
 
2
 
/
 
2
 
 T cells in vitro, and the inability to in-
duce EAE in these mice is corrected by reconstituting them
with B7.1-transgenic APCs. This strongly suggests that the
induction of costimulatory activity on APCs is defective
(5). Moreover, naive T cells from CD40 ligand 
 
2
 
/
 
2
 
 ani-
mals display normal polyclonal as well as Ag-specific re-
sponses (8). This raises the possibility that the immunologi-
cal abnormalities seen as a result of mutated CD40 or
CD40 ligand are in fact due to defective upstream events in
the initiation of acquired immunity, i.e., during the presen-
tation of Ag and priming of naive T cells.
Contact hypersensitivity (CHS) is a T cell–mediated re-
sponse dependent on intact DC functions. During the in-
duction phase of CHS, these functions include Ag capture
in the skin, Ag processing, transport to lymphoid tissues
such as draining lymph nodes (DLNs), and Ag presentation
to naive T cells (1, 9–12). In this study, we investigate the
in vivo role of CD40–CD40 ligand interactions on multi-
ple DC functions using CD40 ligand 
 
2
 
/
 
2
 
 mice and CHS
as the model system. We provide in vivo evidence that
CD40–CD40 ligand interactions play a critical role in reg-
ulating the transport of Ag by epidermal DCs to DLNs and
subsequently the initiation of acquired Ag-specific T cell–
mediated immunity.
 
Materials and Methods
 
Mice.
 
Specific pathogen–free C57BL/6 mice were obtained
from the National Cancer Institute Frederick Cancer Research
Facility Animal Production Area (Frederick, MD), and CD40
ligand 
 
2
 
/
 
2
 
 mice were obtained from The Jackson Laboratory.
The animals were maintained in facilities approved by the Associ-
ation for Assessment and Accreditation of Laboratory Animal
Care, in accordance with current regulations of the United States
Department of Health and Human Services. All animal proce-
dures were reviewed and approved by the Institutional Animal
Care and Use Committee. Mice were 12–16 wk old at the start
of each experiment.
 
Induction and Elicitation of CHS Responses.
 
0.4 ml (2 
 
3 
 
200
 
m
 
l) of a 0.5% solution of FITC (Sigma-Aldrich) prepared in ace-
tone/dibutylphthalate (1:1) was applied to the shaved abdomens
of mice. 6 d later, CHS was elicited by painting the dorsal and
ventral surface of each ear with 5 
 
m
 
l of 0.5% FITC. Ear thickness
was measured using an engineers’ micrometer (Mitutoyo) 24 h
after challenge and compared with ear thickness before challenge.
Specific ear swelling was calculated by subtracting the back-
ground swelling of mice that were not sensitized but challenged.
In experiments where elicitation of CHS was not required, mice
were killed 12 or 18 h after sensitization. Mice killed 18 h after
sensitization were the source of abdominal skin resected to pre-
 
pare epidermal sheets for immunostaining or axillary, brachial,
and inguinal DLNs, which were removed and used for immu-
nostaining and DC purification. Mice killed 12 h after topical ap-
plication of FITC were the source of abdominal skin resected to
prepare epidermal sheets for cytokine detection by ELISA.
 
Isolation of DCs from DLNs.
 
Mice were killed and axillary,
brachial, and inguinal DLNs were excised. Single-cell suspensions
were prepared from pooled DLNs taken from individual mice
and DCs enriched by density gradient centrifugation as previ-
ously described (13). DCs were first assessed by direct examina-
tion using light microscopy. For each mouse in an experimental
group (
 
n
 
 5 
 
5), five counts were made and the mean number of
total DCs 
 
6 
 
SD per DLN was calculated. Only cells showing a
clear spiny appearance or well defined filiform and mobile cyto-
plasmic projections were considered as DCs. Cells exhibiting
only pseudopod-like projections were not counted as DCs. In
addition, DCs were also evaluated by May-Grünwald-Giemsa
staining, immunocytochemistry of cytospin preparations, and
flow cytometry.
 
FACS
 
®
 
 Analysis.
 
DCs purified from DLNs were incubated
with primary Abs or isotype-matched controls for 35 min at 4
 
8
 
C.
DCs were then washed in cold blocking buffer (saline solution
containing 0.1% BSA and 0.5% FCS), incubated with second-
step reagents for 30 min at 4
 
8
 
C, and washed before analysis. As
FITC was used as the sensitizer, gating on this fluorochrome was
used concomitantly with forward and side scatter parameters to
retrieve information only on FITC-bearing DCs. Primary Abs
included B7.1–PE, B7.2–PE, CD8a–PE, CD11c–PE, CD14–PE,
biotinylated anti-CD40, and anti–CD40 ligand (all from Phar-
Mingen) and biotinylated anti–MHC class II (Accurate Chemical).
NLDC145 mAb to mouse DCs was from Serotec. PE-labeled or
biotinylated isotype-matched Abs were from PharMingen. Sec-
ond and third step reagents included biotinylated goat anti–rat
Abs (Vector Labs.) and streptavidin Cy-5 (Southern Biotechnol-
ogy), respectively. Single- and two-color analyses were per-
formed using a Coulter Profile and ELITE V instrument (Coulter
Immunology). Results are expressed as the percentage of positive
DCs within the population of FITC-carrying DCs.
 
Epidermal Sheet Preparation and Immunostaining.
 
Mice were
killed and the abdominal skin was shaved and resected. Fat was
mechanically removed and the skin floated, dermis side down, in
a 0.5 M solution of EDTA for 1 h at 37
 
8
 
C to achieve separation
of the epidermis from the dermis. Epidermal sheets were then
rinsed twice in isotonic saline solution (Baxter), fixed in cold ace-
tone for 25 min, and washed three times in blocking buffer. Epi-
dermal sheets from each experimental group of animals (usually
five) were pooled for analysis and incubated with Abs to the DC
Ag DEC205 (Rat mAb NLDC145; Serotec) at a dilution of 1:50.
A rat mAb to Thy1.2 (American Type Culture Collection) was
used at a dilution 1:100 to identify dendritic epidermal T cells
(DETCs). Appropriate isotype-matched Abs (PharMingen) were
used as controls for specificity. Secondary reagents included biotin-
ylated anti-rat Abs (Vector Labs.) at a dilution of 1:300 and alka-
line phosphatase (1:350) or peroxidase (1:250) conjugated to
streptavidin (Biosource International). Red color was developed
using a Fast Red™ developing kit from DAKO and blue color
with True Blue–peroxidase substrate (Kirkegaard & Perry Labs.).
Samples developed with peroxidase were previously blocked us-
ing a 3% solution of H
 
2
 
0
 
2
 
 for 15 min. A microscope with a cali-
brated grid was used to calculate the number of positive cells per
square millimeter, evaluating at least 20 random fields per sample.
 
Immunostaining of Frozen Sections of DLN.
 
Pooled DLNs from
each experimental group were fixed in cold acetone, preincu- 
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bated with blocking buffer for 15 min, and then incubated with an
alkaline phosphatase–conjugated mAb specific to FITC (Sigma-
Aldrich) at a 1:100 dilution. An appropriate isotype-matched Ab
(PharMingen) was used as a control for specificity. FITC-positive
 
cells in the DLNs were visualized with a Fast Red™ developing
kit (DAKO). Counterstaining of DLN sections was performed
using methyl green.
 
Determination of Epidermal TNF-
 
a
 
 Levels by ELISA.
 
Epidermal
Figure 1.  LCs, DETCs, and lymph node DCs are similar in number and morphology in C57BL/6 and CD40 ligand 2/2 mice. Epidermal sheets
from normal C57BL/6 (a, c) or CD40 ligand 2/2 (b, d) mice were examined for the presence of epidermal DCs and DETCs. LCs are stained red (a–d),
and Thy1.21 DETCs are stained blue (c, d) by using the Fast Red™ and True Blue™ peroxidase substrate systems, respectively. Purified DCs from
lymph nodes of normal C57BL/6 (e) or CD40 ligand 2/2 (f) mice were stained with May-Grünwald-Giemsa stain (e, f). The difference in color inten-
sities between e and f could be due to the fact that these samples were stained at different times. Original magnifications: a–d, 3350; e and f, 3700. 
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sheets from unsensitized and sensitized mice were prepared as de-
scribed above. Each tissue sample was disrupted in a Dounce ho-
mogenizer with 0.5 ml of lysis buffer (4 M guanidium isothiocy-
anate, 0.5% sodium sarcosine, 25 mM sodium citrate, and 0.1 M
2-ME). The protein was desalted by ethanol precipitation and
centrifuged at 10,000 
 
g
 
. Protein pellets were washed with ice cold
70% ethanol and then homogenized once more in 0.5 ml of 0.1 M
sodium carbonate buffer, pH 8.0. The concentration of TNF-
 
a
 
per sample of epidermal lysate was determined using a sandwich
ELISA. Capture Abs, biotinylated Abs, and rTNF-
 
a
 
 were pur-
chased from PharMingen and used according to the manufac-
turer’s instructions. The test was considered positive if the absor-
bance value of the experimental group was at least 3 SD greater
than the OD of the negative control. Generally, the limit of de-
tection for TNF-
 
a
 
 was no less than 1 ng/ml. The amount of
TNF-
 
a
 
 present was normalized for all the samples by comparing
it with the total protein concentration of each sample. Total pro-
tein concentration was determined using the bicinchoninic acid
(BCA) method (Pierce Chemical Co.).
 
Administration of rTNF-
 
a
 
 and Anti-murine CD40 Ab.
 
100 ng
of recombinant murine TNF-
 
a
 
 (
 
,
 
0.1 ng endotoxin per micro-
gram of TNF-
 
a
 
; Genzyme) in 50 
 
m
 
l of sterile isotonic, endo-
toxin-free saline solution (Baxter) was injected intradermally into
each ear. Control animals received the same volume of saline so-
lution only. 18 h later, mice were killed, their ears were resected,
and epidermal sheets were prepared for immunostaining to detect
DCs as already described. 200 
 
m
 
g of rat anti–murine CD40
(Clone IC10, endotoxin free; provided by Dr. M. Howard,
DNAX, Palo Alto, CA) or rat control isotype (PharMingen)
were injected intraperitoneally in sterile, endotoxin-free saline
solution. Mice were killed 18 h later, abdominal skin was excised,
and the frequency of DCs in the epidermis was determined as de-
scribed above.
 
Statistical Analyses.
 
Data were expressed as the mean 
 
6 
 
SD or
SE. Statistical analyses were performed using two-tailed Student’s
 
t
 
 tests. A
 
 P 
 
value 
 
# 
 
0.05 was considered significant (
 
*
 
). Unless in-
dicated otherwise, all experiments were performed at least twice
and were scored by more than one investigator, each blinded to
the experimental protocols employed. Each experimental group
consisted of at least five mice, and the epidermal sheets of each
group of mice were pooled for analysis. A microscope with a cal-
ibrated grid was used to calculate the number of epidermal DCs
per square millimeter, and at least 20 random fields were exam-
ined per sample.
 
Results and Discussion
 
We first examined dendritic epidermal Langerhans cells
(LCs) in the epidermis of normal C57BL/6 (Fig. 1 a) and
CD40 ligand 
 
2
 
/
 
2
 
 (Fig. 1 b) mice by immunohistochemis-
try and found that these animals exhibited no striking dif-
ferences in either LC counts or morphology. Another cell
population of the epidermis, the Thy1.2
 
1
 
 DETCs (14), was
also present in normal skin of control C57BL/6 (Fig. 1 c)
and CD40 ligand 
 
2
 
/
 
2
 
 (Fig. 1 d) mice in relatively equal
numbers. Likewise, DCs isolated from the lymph nodes of
normal, unsensitized C57BL/6 (Fig. 1 e) and CD40 ligand
 
2
 
/
 
2
 
 (Fig. 1 f) mice showed no obvious morphological
differences, nor were there any differences in the number
of DCs isolated from the lymph nodes of these mice (data
not shown). Thus, CD40 ligand does not appear to be es-
sential for the development and congregation of LC and
 
DETC populations in the skin or the presence of resident
DCs in lymph nodes.
It is well documented that cutaneous hapten sensitization
induces LCs to migrate out of the skin (1, 9–12). Thus, we
next addressed the consequence of painting FITC on the
skin of C57BL/6 and CD40 ligand 
 
2
 
/
 
2
 
 mice (Fig. 2). As
anticipated, the number of LCs was reduced in the epider-
mis of sensitized C57BL/6 control (Fig. 2, b and e) mice
compared with unsensitized (Fig. 2, a and e) mice. In con-
trast, unexpectedly, we found that LC migration is dramat-
ically reduced after hapten sensitization of CD40 ligand 
 
2
 
/
 
2
 
mice (Fig. 2, d and e) compared with sensitized control
C57BL/6 (Fig. 2, b and e) mice.
The extent of LC migration out of the skin was surpris-
ingly high (80%) compared with other studies reporting
moderate levels of migration, 
 
z
 
20–30% after FITC sensiti-
zation. This discrepancy could be accounted for by the fact
that we stained for the presence of LCs on the basis of
DEC205 expression rather than ATPase activity or Ia Ag
expression, as carried out in other studies (15, 16). In a re-
cent study, we consistently found that more epidermal LCs
stain positive for the marker DEC205 than for ATPase ac-
tivity in untreated mouse skin, implying that not all LCs
possess this enzyme (17). Therefore, the possibility arises
that different subpopulations of LCs may exist in the epi-
dermis, some being more susceptible to becoming mobi-
lized upon epicutaneous FITC painting than others.
Associated with LC migration from the skin is a con-
comitant accumulation of DCs in lymph nodes draining
FITC-sensitized skin, a large proportion of which bears
FITC (18–20). This phenomenon is also defective in
CD40 ligand 
 
2
 
/
 
2
 
 mice. We found that far fewer DCs ac-
cumulate in the DLNs of CD40 ligand 
 
2
 
/
 
2
 
 mice as a
consequence of FITC sensitization compared with normal
control mice (Fig. 3 a). Furthermore, immunostaining of
frozen DLN sections revealed a nonrandom accumulation
of FITC-bearing DCs in the paracortex of the DLNs from
normal (Fig. 3, b and c) animals. In contrast, considerably
fewer Ag-bearing DCs were detected in DLNs from CD40
ligand 
 
2
 
/
 
2
 
 (Fig. 3, d and e) mice. Concomitantly, and
possibly as a consequence of the failure of epidermal LCs to
emigrate and carry Ag to the T cell areas of DLNs, CHS
reactions were substantially decreased in CD40 ligand 
 
2
 
/
 
2
 
animals, compared with the response of positive control
C57BL/6 animals (Fig. 4).
Since FITC was used as a sensitizer, we were able to spe-
cifically analyze the phenotype of FITC-bearing DCs from
DLNs using flow cytometry (Table I). Compared with
wild-type controls, fewer B7.1
 
1
 
 and CD40
 
1
 
 DCs were
found in CD40 ligand 
 
2
 
/
 
2
 
 mice, whereas no difference in
the percentage of cells expressing MHC class II or B7.2 was
observed. Also, fewer DLN DCs from CD40 ligand 
 
2
 
/
 
2
 
mice expressed DEC205, a prominent nonclonal receptor
of the innate immune system involved in Ag presentation
by DCs (21).
Though it has long been known that cutaneous Ag sen-
sitization induces LCs to leave the skin and migrate to
DLNs (1, 9–12), the initial events triggering this process in 
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the skin are not well understood. Studies using anti–TNF-
 
a
 
Abs (22) or rTNF-
 
a
 
 (13) or its receptors (23) have estab-
lished this cytokine as a critical mediator involved in DC
migration from skin and CHS. Cutaneous Ag application
has also been shown to induce mRNA for a variety of
proinflammatory cytokines including TNF-
 
a (24). More-
over, CD40 ligation induces secretion of TNF-a by CD401
basal keratinocytes (25). We therefore speculated that the
lack of LC migration observed in CD40 ligand 2/2 mice
after epicutaneous sensitization may occur as a consequence
of defective TNF-a production within the skin of these
mice. Indeed, analysis by ELISA of the TNF-a content of
epidermal sheets prepared from unsensitized and sensitized
skin of C57BL/6 and CD40 ligand 2/2 mice revealed
Figure 2. Impaired migration of epidermal DCs in CD40 ligand 2/2 mice upon Ag
sensitization. Epidermal sheets from C57BL/6 (a, b) and CD40 ligand 2/2 (c, d) mice
were stained for LCs (shown in red; as described). Mice in panels b and d were sensitized
with FITC, and those in panels a and c were not. Yellow spots of FITC are still visible in
the epidermis (b and d, arrows). DCs nearly disappear from the epidermis of control
mice after FITC sensitization (b), but they are clearly present around FITC-positive re-
gions in the epidermis of CD40 ligand 2/2 mice (d). To determine the frequency of
epidermal DCs, we pooled epidermal sheets from at least five mice per experimental
group (*P , 0.001), and at least 20 random fields were examined per sample. Results are
expressed as DCs per square millimeter of epidermis (e). Original magnification, 3350.2016 CD40–CD40 Ligand Interactions In Vivo Regulate Dendritic Cell Migration
differences in TNF-a production between these mouse
strains. In contrast to C57BL/6 mice, whose baseline
TNF-a levels in untreated skin increased after Ag-sensiti-
zation, CD40 ligand 2/2 mice exhibited high levels of
TNF-a in unsensitized skin equivalent to the levels seen in
sensitized wild-type mice, which decreased after sensitiza-
tion (Fig. 5 a). Thus, LCs may not mobilize after hapten
sensitization because TNF-a production is aberrantly regu-
lated in the epidermis of CD40 ligand 2/2 mice, both be-
fore and after epicutaneous sensitization.
To rule out the possibility that the altered LC migration
in the mutant mice was due to some intrinsic defect rather
than the aberrant regulation of TNF-a production, we
next had to address whether LC migration could be re-
stored in CD40 ligand 2/2 mice if an exogenous source
of TNF-a was provided. In fact, by administering rTNF-a
Figure 3. Ag-sensitized CD40 ligand 2/2 mice have reduced numbers of total
and Ag-bearing DCs in the DLN. DLNs from FITC-sensitized C57BL/6 (a, left)
and CD40 ligand 2/2 (a, right) animals (n 5 5) were removed 18 h after sensitiza-
tion, and the total number of DCs per DLN was determined for individual mice
(a). To identify Ag-carrying DCs in situ, frozen sections of lymph nodes draining
FITC-sensitized skin were stained with an alkaline phosphatase–labeled mAb spe-
cific for FITC and developed using the Fast Red™ substrate system. Ag-bearing
DCs (stained red) are congregated in the paracortical areas of DLNs from C57BL/6
(b, c) but not CD40 ligand 2/2 mice (d, e). Panels b and d are low magnifications
(3130), whereas panels c and e are high magnifications (3260). Sections were
counterstained with methyl green.2017 Moodycliffe et al.
intradermally into the skin of CD40 ligand 2/2 mice, LCs
were induced to migrate out of the epidermis (Fig. 5 c) to
the same extent as observed in C57BL/6 mice treated in
the same manner (Fig. 5 b). Likewise, LC mobilization was
also induced when the missing CD40 ligand signal was re-
established by injecting agonistic anti-CD40 mAb (26, 27)
into CD40 ligand 2/2 (Fig. 5 e) and control (Fig. 5 d)
mice, thus ruling out an intrinsic LC migratory defect and
indicating an essential role for CD40 signaling and TNF-a
in LC migration.
It is intriguing that unsensitized CD40 ligand 2/2 mice
produced significantly higher amounts of TNF-a in their
epidermis compared with wild-type age-matched control
mice. It is possible that TNF production is enhanced in these
mice to compensate for the deficiency in CD40 ligand pro-
duction. Although unexpected, this finding is not too sur-
prising considering the fact that TNF-a and CD40 ligand
are both members of the TNF-a ligand superfamily. Thus, it
would appear that TNF-a production and CD40 ligand ex-
pression are intimately linked. Indeed, in inflammatory
bowel diseases such as Crohn’s disease and ulcerative colitis,
which are characterized by the local production of cytokines
such as TNF, there is a significant increase in the number of
CD40- and CD40 ligand–positive cells in the inflamed mu-
cosa (28). Furthermore, decreased TNF production as well
as impaired inflammatory responses have been described in
CD40 ligand 2/2 mice infected with Leishmania (5). Re-
cently, it has also been demonstrated that increased TNF-a
production and induction of neuronal injury occur when ac-
tivated microglia, which exhibit increased CD40 expression,
are treated with CD40 ligand (29).
Although our data points to the aberrant regulation of
TNF-a production in the skin of CD40 ligand 2/2 mice,
accounting for the defect in DC migration, it is difficult to
explain how FITC sensitization would decrease TNF-a lev-
els in these mice. One possible mechanism may be via the
overproduction of IL-10, an antiinflammatory cytokine re-
cently demonstrated to play an important role in inhibiting
epidermal LC migration from sensitized skin to DLNs (30).
The cellular source of CD40 ligand in the skin is unclear.
Conventional T cells are an obvious candidate because they
express CD40 ligand upon activation. However, they are
not normally present in the skin, nor are they significantly
recruited into the skin during the initiation of CHS (refer-
ence 31 and data not shown). Mast cells, on the other
hand, express functionally active CD40 ligand (32) and are
Figure 4. CD40 ligand 2/2 mice have de-
fective CHS responses. Mice were epicutane-
ously sensitized on their shaved abdomens with
FITC and challenged on both of their ears 6 d
later. Ear thickness was measured immediately
before and 24 h after challenge using an engi-
neers’ micrometer. Background swelling was
obtained from control animals that were not
sensitized but were challenged. Results are ex-
pressed as the mean 6 SE of at least five mice
per experimental group (*P , 0.001).
Table I. Phenotype of FITC-bearing DCs from DLNs of 
C57BL/6 and CD40 Ligand 2/2 Mice
Percent staining
Markers C57BL/6 CD40 ligand 2/2
CD80 (B7-1) 49 15
CD86 (B7-2) 96 95
CD40 33 ,1
CD40 ligand 0 0
DEC205 60 23
MHC class II 99 98
CD11c 67 30
CD14 22 9
CD8a 73 37
DEC205/MHC class II 57 30
DEC205/CD11c 45 10
DEC205/CD14 20 5
MHC class II/CD8a 72 36
DCs from DLNs of FITC-sensitized mice were purified by density
gradient centrifugation to enrich for DCs. They were then analyzed by
flow cytometry for the markers shown. Greater than 12,000 events were
acquired for each experimental group. Cells were first gated on the basis
of high forward and side scatter to identify DCs. They were then gated
on the basis of FITC expression; z5,000 gated (FITC-positive) cells
were analyzed for PE and Cy-5. Results are expressed as the percentages
of DCs that are positive for a given marker within the population of
FITC-carrying DCs.2018 CD40–CD40 Ligand Interactions In Vivo Regulate Dendritic Cell Migration
found in normal skin, although in low numbers. They pos-
sess an arsenal of powerful pharmacological mediators and,
in addition, are the only cells known to constitutively pro-
duce and store TNF-a (33), ready for immediate release
early during an inflammatory reaction. Nonlymphoid cells
such as platelets may also serve this function. They can be
detected localizing inside (34) and outside (35) dermal
venules at sites of acute inflammation. Furthermore, human
umbilical vein endothelial cells, which constitutively ex-
press CD40, can be induced to release inflammatory cyto-
kines such as TNF-a as a result of triggering by inducible
CD40 ligand on activated platelets (36).
Arguably, the finding that mast cell–deficient mice dis-
play normal CHS responses raises doubt that mast cells may
play a critical role in regulating DC migration and conse-
quently the induction of CHS. Indeed, severe depletion of
platelets in mast cell–deficient mice with antiplatelet Ab has
been demonstrated to strongly inhibit CHS responses (37),
therefore supporting a role for platelets in this process.
However, although antiplatelet Ab treatment markedly re-
duces CHS responses in mast cell–deficient mice, the same
treatment of normal 1/1 littermate control mice only
minimally affects CHS responses (37). Thus, mast cell–defi-
cient mice are unique in that they exhibit a significantly
greater dependence on platelets compared with wild-type
control mice for full manifestation of CHS ear swelling re-
sponses. Therefore, both mast cells and platelets likely play
a role in regulating CHS responses, although to differing
extents, with mast cells likely playing a more prominent
role in normal mice, perhaps by influencing LC migration
via CD40–CD40 ligand interactions in the skin. Interest-
ingly, we found that mast cells fail to accumulate in the
dermis of sensitized CD40 ligand 2/2 mice compared
with wild-type controls (data not shown).
Figure 5. Reconstituting CD40 signaling or
injecting TNF-a restores migration of epider-
mal DCs in CD40 ligand 2/2 mice. TNF-a
levels in the epidermis of untreated (2) or sen-
sitized (1) wild-type and CD40 ligand 2/2
mice were determined by ELISA using protein
extracts of epidermal sheets (a). The data are re-
ported as TNF-a/total protein (ng/mg) and
represent the mean 6 SD of each sample tested
in triplicate. To assess the role of local TNF-a
on DC migration, wild-type (b) and CD40
ligand  2/2 (c) mice were injected with saline
(b and c, left bars) or rTNF-a (b and c, right
bars). Mice were then killed 18 h later to re-
move the ears, prepare epidermal sheets, and
count epidermal DCs in wild-type (b) and
CD40 ligand 2/2 (c) mice. To reconstitute
CD40 signaling in wild-type (d) and CD40
ligand 2/2 (e) mice, anti–murine CD40 (d
and e, right bars) or control Ab (d and e, middle
bars) was injected intraperitoneally and the
mice were killed 18 h later. The number of epi-
dermal DCs was then counted in wild-type (d)
and CD40 ligand 2/2 (e) mice. Epidermal
sheets from each experimental group were
pooled for immunostaining. Results are ex-
pressed as the mean 6 SD of DCs per square
millimeter of epidermis. A minimum of five an-
imals was used per group (*P , 0.001).2019 Moodycliffe et al.
In conclusion, our findings reveal that CD40–CD40
ligand interactions in vivo play a key role in regulating the
migration of Ag-bearing epidermal DCs to DLNs and sub-
sequently the initiation of an acquired immune response.
They also imply that an important outcome of these inter-
actions is the production of cutaneous TNF-a, a known
mediator of epidermal DC migration. Thus, CD40–CD40
ligand interactions might be considered as a functional
bridge between innate responses and the initiation of ac-
quired immunity.
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